Following our recent announcement that Principal Naomi Pearce (Patent Star 2021) was honoured with a Managing IP (MIP) Patent Star 2021 awards, Pearce IP’s Special Counsel Patent...
Diagnostic tests that rely on a naturally occurring phenomenon patent eligible in Australia On 18 June 2021, the Full Court of the Federal Court confirmed in Ariosa Diagnostics,...
Date: 22 June 2021Forum: Australian Patent OfficeDelegate: Xavier Gisz Background As part of the Raising the Bar amendments introduced to the Patents Act 1990 (Cth) in 2013,...
10 June 21 | The UK's NICE published final draft guidance recommending adalimumab, etanercept and infliximab for the treatment of moderate rheumatoid arthritis on the NHS....
07 Jun 21 | Celltrion launched Remsima SC® (subcutaneous infliximab biosimilar) in Canada. Remsima SC® is indicated for the treatment of rheumatoid arthritis. 07 Jun 21 | Merck...
In September 2020, Pearce IP reported on a significant Australian Patent Office decision, which held that a patent term extension (PTE) request must be based on the first...
Pearce IP is proud that its patent practitioners feature again in the Managing IP Awards 2021. Congratulations to Naomi Pearce, Principal Lawyer, Patent Attorney and Trade Mark...
Pearce IP recently reported on recommendations made by an independent review into the Australian patent system to overhaul the way in which patent litigation proceeds in...
Date: 11 June 2021Court: Federal Court of AustraliaJudge: Beach J Background Under Australian law, patents that cover certain pharmaceutical inventions are eligible for an...
Date: 08 June 2021 Forum: Australian Patent Office Delegate: Felix White Background This case concerned a dispute as to inventorship of an apparatus for detaching surgical...
31 May 21 | Celltrion will launch Yuflyma® (biosimilar adalimumab) in the EU in June, as reported by the Korea Herald. Citing ‘industry sources’ and a Celltrion official, the...
Date: 02 June 2021Forum: Australian Patent OfficeDelegate: Damian Triffett Background In June 2021, the Australian Patent Office handed down a much-anticipated CRISPR decision,...
At the end of 2020, we reported on a Government review of the Australian patent system and its accessibility for small and medium sized enterprises (SMEs). The Patent...
24 May 21 | IN | Zydus Cadila announced it has launched Ujvira (trastuzumab emtansine) in India. Ujvira is an antibody drug conjugate biosimilar and is available in 100mg and...
12 May 21 | Celltrion released its Q1 2020 financial results, reporting that YoY sales of Celltrion biosimilars increased by 23%. Celltrion announced that it is planning to...
11 May | US | Alvotech filed a federal lawsuit against AbbVie in the US District Court of the Eastern District of Virginia, seeking to clear patent barriers relating to its...
On 11 May 2021, Treasurer Josh Frydenberg announced that the 2021-2022 Australian Federal Budget would introduce a Patent Box tax break. This regime is designed to encourage...
IP waivers alone are nowhere near enough to increase COVID-19 vaccine access for developing countries, but US support for such waivers will create enormous pressure on existing...
01 May 21 | Samsung Bioepis announced a new study demonstrating the structural, physicochemical and biological similarity between its SB11 (proposed ranibizumab biosimilar) and...
Date: 5 May 2021Court: Full Court of the Federal Court of AustraliaJudges: Beach, Moshinsky and Thawley JJ Background Australian Patents AU2012304245 and AU2013100458 (Patents),...
In light of the COVID-19 vaccine supply shortages in Australia, it was refreshing to hear NSW Premier Gladys Berejiklian announce yesterday that the NSW Government will establish...
23 April | Boehringer Ingelheim announced results from a Ph III switching study of Cyltezo® (biosimilar adalimumab) with Humira® produced similar clinical outcomes in terms of...
Pearce IP is proud to announce that our team of patent and trademark lawyers and attorneys have once again been listed as Australia's leading practitioners in the World...
As a second wave of COVID-19 ravages India, the rest of the world should be paying close attention to the reported meltdown of its pharmaceutical manufacturing capabilities and...
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
